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ABSTRACT
The ability to alter the genes of future generations no longer
belongs in the realm of science fiction. The genetic modification
capabilities of modern science are advancing rapidly.
Mitochondrial replacement therapy (MRT) represents the first
crossing of the germline barrier in humans, and as of February
2015, it is the first procedure of its kind to be legalized in the
Western world. How Congress decides to regulate MRT will
influence future regulation of all genetic manipulation
technologies. This brief argues that the current patchwork
regulatory framework established in the United States is
insufficient to deal with the complex issues MRT presents. As such,
the creation of a new regulatory agency specifically focused on the
oversight of reproductive and genetic biotechnologies may be
necessary to balance the goals of ensuring the safety of research
participants, promoting public debate, and stimulating continued
scientific progress.

INTRODUCTION
The field of reproductive technology is renowned for pushing
boundaries and contributing innovative approaches to the pursuit of fertility
enhancement. In vitro fertilization (IVF), for example, was “recognized by a
Nobel Prize in physiology and medicine . . . [which] all but vanquished the
scourge of infertility.”1 Yet, with the convergence of reproductive sciences
and genetic technologies, IVF is on its way to being supplanted by
unprecedented breakthroughs that will transform reproductive medicine as
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we know it.2 These breakthroughs involve germline modification, a form of
human genetic engineering that aims to alter the genes in sperm, eggs cells
or embryos.3 Unlike somatic modifications,4 where changes in the genetic
makeup die with their bearer, germline modifications affect every cell in the
body, not only in the children that result from the procedure, but in all
succeeding generations.5
In the face of such historic developments in our scientific
capabilities, legislators must reexamine how to regulate the development
and use of these innovations in the United States. This brief focuses on
mitochondrial replacement therapy (MRT), which some deem a test case
for the regulation of germline modification procedures.6 MRT is a technique
that prevents a host of severe neurological disorders caused by mutant
mitochondrial DNA (mtDNA) by replacing it with healthy mtDNA
extracted from donated eggs.7 Because the changes are heritable, this
procedure is a form of germline engineering. Although the technology has
faced both praise and controversy,8 the development of MRT is undeniably
historic9:
First, MRT represents the first ever crossing of the germline barrier.
Second, MRT constitutes the first ever form of organelle, indeed
whole cytoplasmic replacement therapy. Third, MRT represents the
first ever gene therapy that is IVF based. Fourth, MRT serves as a
regulatory test case for all future cutting-edge reproductive
technologies. Fifth, MRT irrevocably alters the face of assisted
reproduction from a discipline focused on infertility to one with a far
broader portfolio.10
2
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Health].
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This brief argues that the patchwork regulatory framework currently
established in the United States is insufficient to deal with the complex
issues at play. Instead, Congress should create a new regulatory agency to
focus on the oversight of reproductive and genetic biotechnologies.

I. THE SCIENCE BEHIND MITOCHONDRIAL REPLACEMENT THERAPY
Our bodies are formed from a collection of cells, each containing
forty-six chromosomes—tightly-packed groups of DNA that provide the
blueprint for our development and functioning.11 Each cell contains a
nucleus that houses almost all our genetic material, and a mitochondrion,
which acts as the cell’s battery pack, using oxygen to create energy that
powers the cell.12 The mitochondrion also contains a small amount of its
own genetic material, called mitochondrial DNA (mtDNA).13 In
reproduction, the egg and the sperm each carry half of the required number
of chromosomes and combine their nuclear DNA to create a zygote, which
divides to form an embryo.14 mtDNA, however, is unique in that it is not
created by a combination of its parents’ cell DNA.15 Instead, individuals
inherit mtDNA exclusively from their mothers.16
Although mtDNA accounts for a very small percentage of the
human genome, mitochondrial gene mutations can cause severe
neurological consequences.17 Mutant mtDNA “gives rise to a broad range of
inborn errors of energy metabolism, the manifestations of which are highly
disabling and often fatal.”18 More devastatingly, because mtDNA is passed
on from the egg, all children from affected women inherit these
mitochondrial mutations.19
MRT is a new fertility treatment that could prevent genetic diseases
that stem from mutant mtDNA. The procedure works by removing the
nuclear DNA from the target egg’s defective mtDNA and placing it within a
J. Ravindra Fernando, Note, Three’s Company: A Constitutional Analysis of
Prohibiting Access to Three-Parent In Vitro Fertilization, 29 NOTRE DAME J. L.
ETHICS & PUB POL’Y 523, 528 (2015).
12
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16
Fernando, supra note 11, at 529.
17
Fischbach et al., supra note 7, at 186.
18
Adashi, supra note 1, at 1331.
19
Fischbach et al., supra note 7, at 186.
11

124

MITOCHONDRIAL REPLACEMENT THERAPY [Vol. 15

donated egg with healthy mtDNA.20 The nuclear DNA of the donated egg is
similarly removed so that the healthy mtDNA is the only contribution by
the donor.21 The need for MRT is apparent for families carrying mtDNA.
While the treatment does little to help those currently living with
mitochondrial disease, it allows the second generation transmission of
mtDNA-based diseases to be circumvented.22 For families carrying mtDNA,
MRT is a source of hope for a future with genetically related children.

II. CONSIDERATIONS FOR SELECTING A REGULATORY FRAMEWORK
FOR GERMLINE MODIFICATIONS IN THE UNITED STATES
A. MRT as a Regulatory Test Case
The significance of the resulting germline modification in MRT is
small since mtDNA only “represents less than 0.2% of the total human
genome.”23 The potential and perils of germline modification can be seen
more vividly in other rapidly developing technologies such as ZFN,
TALEN, CRISPR-Cas9 and ARCUS, which provide the ability to induce
site-specific DNA changes in the genome.24 However, this paper focuses on
MRT as the regulatory test case for all future reproductive genetic
technologies because a discussion of the regulatory regime behind MRT is
both more relevant and salient. MRT represents the first ever crossing of the
germline barrier in humans, and is the first procedure of its kind to be
legalized in the Western world.25
In February 2015, both the House of Commons and the House of
Lords in the United Kingdom overwhelmingly approved the use of MRT in
humans,26 making it the first country in the world to allow mitochondrial
replacement therapy.27 It has been noted that “[t]he regulatory adjudication
of MRT in the United Kingdom, several years in the making, was
exemplary in its focus on safety, ethics, and public receptivity.”28 With
20
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precedent set by the international community, and escalating pressure from
within the country,29 Congress must soon decide whether and how to
regulate reproductive genetic technologies. Thus, Congress’s treatment of
MRT may lay the foundation for how advances in this field will be dealt
with in the future.

B. Framing the Options and Criteria
For germline modification technologies like MRT, currently no
“federal or state legislation specifically governs this advanced reproductive
technology” in the United States.30
In this context, there are several regulatory pathways that may be
adopted to provide oversight for germline modification technologies.
1. Maintain the Status Quo: The regulation of germline
modification technology may be left to be regulated by
market forces in the private sector.
2. Cede Authority to the FDA: Authority to regulate
germline modification technologies may be granted to
the FDA.
3. Create a New Independent Regulatory Agency:
Congress could enact legislation authorizing the
creation of a new regulatory agency focused
specifically on the oversight reproductive and genetic
biotechnologies.
If the regulatory treatment of MRT is to serve as a foundation for
the regulation of future germline modification technologies, each of the
possible alternatives available to Congress must be compared and tested.
Although there may be a variety of relevant and important goals, this brief
will focus on the ability of a regulatory framework to:
•

Maximize safety and well-being for research
participants.

•

Encourage full and open debate.

•

Ensure and enable the continued advancement of
scientific progress.

The following sections will consider each of the presented regulatory
alternatives individually against these three criteria.

29
30

Fernando, supra note 11, at 527.
Id. at 526.
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III. OPTION ONE: MAINTAINING THE STATUS QUO
The United States currently employs a patchwork system of
oversight for reproductive genetic technologies.31 There are “no federal
law[s] or promulgated regulations directly addressing the genetic
modification of gametes or early embryos” in humans.32 Various aspects of
reproductive research are covered by certain state laws.33 Although without
any formal regulatory authority, several NGOs and professional
organizations in reproductive medicine have also set practice standards.34
The only source of federal oversight comes from from the National Institute
of Health (NIH) and the Food and Drug Administration (FDA).35 The role
of both these institutions in regulating reproductive technologies like MRT
is both limited and uncertain.
The NIH, for example, considers the “social and ethical
implications of ‘novel gene-transfer research protocols,’” through the
Recombinant DNA Advisory Committee (RAC).36 However, RAC’s
mandate is limited to technology present in the 1980s, and thus, “it
considers only those interventions that involve recombinant DNA.”37 As a
result, because MRT involves cellular surgery rather than recombinant
DNA, it technically falls outside the RAC’s purview despite the fact that
inheritable genetic modifications are involved.38 Regardless, as a matter of
policy, the RAC has stated that it will not review any proposals that involve
the modification of gametes or embryos.39 By refusing to review proposals,
the RAC effectively cut off federal funding for germline modification
research. In April 2015, the NIH more explicitly affirmed that heritable
genetic modifications fall under the Dickey-Wicker Amendment, meaning
that no federal funds will be made available for such research.40 As a result
of the current patchwork framework, the advancement and regulation of
germline modification technology has essentially been left to market forces
and the private sector.
The first option, and likely the easiest, is to maintain the status quo,
leaving regulation to free-market forces. Several writers have suggested
31

Erik Parens & Lori P. Knowles, Reprogenetics and Public Policy: Reflections
and Recommendations, 33 HASTINGS CTR. REP. S1, S10 (2003).
32
Girard Kelly, Comment, Choosing the Genetics of Our Children: Options for
Framing Public Policy, 30 SANTA CLARA HIGH TECH. L.J. 303, 336 (2014).
33
Parens & Knowles, supra note 31, at S12.
34
Kelly, supra note 32, at 336–339.
35
Fernando, supra note 11, at 526–27.
36
Kelly, supra note 32, at 337.
37
Parens & Knowles, supra note 31, at S11.
38
See id.
39
Kelly, supra note 32, at 337.
40
Editorial, Gene Politics, 523 NATURE 5, 6 (2015).
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that, if left to the market, “most regulation will occur informally through the
market interactions of willing consumers and providers of these services
against a background of common law norms, some professional selfregulation, and occasional state legislative intrusions.”41 However, this
patchwork approach is insufficient because it fails to adequately ensure
safety and well-being, full and open public debate, and promote scientific
progress.

A. The Private Sector and Safety & Well-Being
To leave the regulation of reproductive genetic research to the
private sector may be dangerous for research participants and would place
the United States in stark contrast with the approach taken by the rest of the
world.42 In the context of gene therapies, for example, researchers and
clinicians have expressed concern that risks are taken in the private sector
with little understanding of the long-term health consequences.43
Unfortunately, experimental reproductive techniques have been rapidly
introduced on the market “without sufficient prior animal experimentation,
randomized clinical trials, or the rigorous data collection that would occur
in federally funded studies.”44 As summarized by the National Conference
of State Legislatures, “a substantial proportion of research and innovative
therapy in reproductive medicine need not be subject to peer review, may
not conform to current standards for informed consent, and may be offering
services that have never been fully evaluated for safety and efficiency.”45
Germline modification technologies are rife with potential dangers, risks
that have radical implications for the well-being of future generations. Such
a technology demands a public system of oversight that “relies on more than
the discretion of individual researchers and their institutions.”46

B. The Private Sector and Public Debate
In addition to issues of participant safety, allowing the bulk of
germline modification research to remain in the private sector is also
“incompatible with the ideal of conducting such work in the light of
forthright public deliberation.”47 The modification of heritable genes raises
deep ethical questions and complex considerations regarding the well-being
of families and society. The consequences of any side effects of such
41

See John A. Robertson, Procreative Liberty in the Era of Genomics, 29 AM. J.L.
& MED. 439, 483–84 (2003).
42
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Id.
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Id.
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Id.
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treatment may not be foreseeable or expressed until years into the child’s
life or perhaps generations down the line. In addition to the risks of these
procedures to subsequent generations, innumerable challenging questions
arise that cannot be fully answered by science. What sort of procedures do
we consider moral? How do we deal with other countries with different
values and should we be concerned about keeping up with the technological
advancements of other nations? How do you respect the autonomy of those
who consent and willingly engage in such research despite the risks and can
parents’ consent on behalf of their unborn children?48 How do we ensure
equal access to such technology and avoid situations of exploitation and
social injustice?49 How do we address concerns regarding the potential rise
of designer babies and eugenics?50
We, as a society, must decide what risks we are willing to accept
and where we draw the line. “[S]ince scientists are members of a
democratic community who share resources (and all researchers in this
country benefit directly or indirectly from our extraordinary scientific
infrastructure), they are obliged to subject their research to public
scrutiny.”51 A decision as important as whether to allow inheritable genetic
modification should not be left to individual researchers and the private
sector.

C. The Private Sector and Scientific Progress
Finally, the natural secrecy of the private sector may impede the
progression of germline modification research.52 Without public funding,
research and innovation will remain in the hands of the private industry,
who have no incentive to share the fruits of their labor. With the potential
that germline modification technologies hold for saving lives and curing a
host of genetic diseases, public research in this field should be promoted.
Some will argue that the financial incentives of an unregulated free-market
will result in the most technological advancement. However, incentives to
cut corners and accept greater risks in the private sector may eliminate the
therapeutic and financial rewards of germline modifications. Jesse
Gelsinger is a vivid example.
Jesse Gelsinger suffered from ornithine transcarbamylase
deficiency (OTC), a rare metabolic disorder that prevented the body from

48

See Joanna Smolenski, CRISPR/Cas9 and Germline Modification: New
Difficulties in Obtaining Informed Consent, 15 AM. J. BIOETHICS 35, 35-68 (2015).
49
See Parens & Knowles, supra note 31, at S7.
50
Id.
51
Id. at S11.
52
See id. at S10.

No. 1]

DUKE LAW & TECHNOLOGY REVIEW

129

breaking down ammonia.53 He died in 1999 during a gene-therapy
experiment gone wrong at the University of Pennsylvania.54 In the 1990s,
the ability of gene therapy “to cure was thought to be boundless and the
hype was astronomical” as companies invested millions of dollars in the
technology.55 Yet, after a series of revelations regarding serious deficiencies
in informed consent and study design, progress in gene therapy stalled as
public opinion and trust collapsed. “Gene therapy remains an obvious route
to treat OTC . . . [b]ut the memory of what happened to Gelsinger has
slowed progress in gene therapy for any condition.”56
Just like pharmaceutical and the biotech industries, clinical trials are
the lifeblood of reproductive technologies. Profit driven motives to cut
corners on informed consent and safety precautions in order to access
human test subjects increases the likelihood of tragedies such as Jesse
Gelsinger. Contrary to the financial interests of the private sector, avoidable
failures could stymie research in germline modification for decades. In
order to promote technological advancement, and to unlock both the
financial and therapeutic potential it offers, more robust and regulated
safety precautions must be put in place to protect the “fragile nature of the
public trust that sustains research.”57

IV. OPTION TWO: THE FOOD AND DRUG ADMINISTRATION
The authority to regulate germline modification technologies could
be ceded to the FDA. The FDA has already asserted its jurisdiction over
MRT through the Office of Cellular, Tissue, and Gene Therapies of the
Center for Biologics Evaluation and Research.58 This branch of the FDA’s
task is to oversee “human cells used in therapy involving the transfer of
genetic material by means other than the union of gamete nuclei.”59 The
FDA’s claim to MRT rests upon the therapy’s inclusion under the broad
definition of a “drug.”60 A “drug” is defined by the Food, Drug, and
Osagie K. Obasogie, Ten Years Later: Jesse Gelsinger’s Death and Human
Subjects Protection, THE HASTINGS CENTER: BLOG (Oct. 22 2009), http://www.
thehastingscenter.org/ten-years-later-jesse-gelsingers-death-and-human-subjectsprotection.
54
Id.
55
Id.
56
See Editorial, Gene-Therapy Trials Must Proceed with Caution, 534 NATURE
590, 590 (2016).
57
Mark Yarborough & Richard R. Sharp, Public Trust and Research a Decade
Later: What Have We Learned Since Jesse Gelsinger’s Death?, 97 MOLECULAR
GENETICS & METABOLISM 4, 4 (2009).
58
Glenn Cohen, Julian Savulescu & Eli Y. Adashi, Transatlantic Lessons in
Regulation of Mitochondrial Replacement Therapy, 348 SCI. 178, 179 (2015).
59
Id.
60
Kelly, supra note 32, at 342.
53
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Cosmetic Act to encompass anything that is “intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of disease,” or that is
“intended to affect the structure or any function of the body.”61 Although
this option can ensure the safety and efficacy of research participants,
ceding authority to the FDA may not be the best option as it falls short in its
ability to consider well-being, promote public debate, and ensure continued
scientific progress.

A. The FDA and Safety & Well-Being
The advantage for ceding authority to the FDA is that it already
exists and it is arguably ready to exercise oversight, at least on safety and
efficacy grounds. Under the FDA’s existing regulations, approval of MRT
for therapeutic use will require “phased clinical trials pursuant to an
Investigational New Drug application (IND).”62 To gain the FDA’s
approval, the technology will be subject to a “searching review of the
method’s safety and efficacy as well as satisfactory completion of human
trials.”63 Thus, regulation of MRT by the FDA would provide significantly
more comprehensive oversight in ensuring the safety of research
participants.
On the other hand, because the FDA’s mandate is limited to issues
related to safety and efficacy, considerations regarding the “well-being” of
the research participants and of society will be neglected under the FDA’s
authority.64 As discussed above, this is significant because the modification
of heritable genes raises deep ethical questions and considerations regarding
the well-being of families and society. For example, germline modification
techniques such as MRT permanently change the mtDNA in every cell of
the resulting child,65 unlike normal drugs where the doses can be slowly
increased and stopped in the event of a serious side effect. The
consequences of any side effects may not be foreseeable or expressed until
years into the child’s life. As such, classifying MRT as “drugs likely
encompasses too broad of a definition and offers inadequate regulation for a
drug that would change the structure and function of the human body.”66 It
would be best if technologies like MRT did not fall exclusively within
FDA’s mandate.67

61

Id. at 342-43.
Id. at 337–38.
63
Fernando, supra note 11, at 526–27.
64
Kelly, supra note 32, at 345–46.
65
See ASS’N OF REPROD. HEALTH, supra note 3, at *5.
66
Kelly, supra note 32, at 343.
67
Parens & Knowles, supra note 31, at S12.
62
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Congress may choose to remedy this by endowing the FDA with
the power to consider moral and philosophical issues of the technology.68
To do so will require Congress to expand the FDA’s regulatory authority
without distorting its current three-tier classifications.69 Such a radical
change would require reorganization of the agency and its members.70 With
the complexity and expenses related to such reorganization in mind, it
would make more sense for Congress to focus its resources on creating a
new independent agency and framework for oversight.71

B. The FDA and Public Debate
Due to the complex and controversial nature of genetic
modification, decisions regarding germline modification should be informed
by collaborative public discussions on both safety and well-being
concerns.72 In this respect, the FDA is also severely lacking. In the United
States, discussions regarding MRT have been limited to a few conversations
among experts, with relatively little input from the public.73 In fact, the
FDA has never officially even considered clinical trials for MRT. The only
time it was discussed was in early 2014 during a discussion regarding
“oocyte modification” by the FDA’s Cellular, Tissue, and Gene Therapies
Advisory Committee.74 No official conclusion from the meeting was ever
provided and the results were merely summarized by the chairman with the
brief comment that “[s]everal panelists felt ‘there was probably not enough
data in animals . . . to move on to human trials without answering a few
additional questions.’”75 The FDA has also commissioned the committee of
the Institute of Medicine to provide an ad hoc review of the ethical and
social considerations of novel approaches to treating mitochondrial DNA
diseases.76 However, “only two of the planned committee sessions will be
available to the public.”77

68

Kelly, supra note 32, at 345–46.
See id. at 344–46.
70
Id.
71
Id.
72
See Mark S. Frankel and Audrey R. Chapman, Human Inheritable Modifications:
Assessing Scientific, Ethical, Religious, and Policy Issues, AM. ASS’N FOR THE
ADVANCEMENT OF SCI., Sept. 2002, at 3–5, https://www.aaas.
org/sites/default/files/migrate/uploads/germline.pdf.
73
Cohen et al., supra note 58, at 179.
74
Id.
75
Id.; see also Sharon Begley, U.S. FDA Weighs Evidence on Producing ‘ThreeParent’ Embryos, REUTERS (Feb. 25, 2014), http://www.reuters.com/article/us-usahealth-ivf-idUSBREA1O1WL20140225.
76
Cohen et al., supra note 58, at 179.
77
Id.
69
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C. The FDA and Scientific Progress
Finally, the FDA’s recent actions have done little to create
confidence in its ability to foster safe but productive research in this field.
As mentioned, MRT was largely ignored in a brief discussion by the FDA’s
Cellular, Tissue, and Gene Therapies Advisory Committee in 2014.78 No
further FDA action is expected until the Institute of Medicine report has
been released, which is estimated to be around early 2016.79 Meanwhile,
“any relevant INDs submitted would remain on hold.”80
In terms of the goal of promoting scientific progress, the FDA is not
the ideal option for regulating germline modifications because it is not
efficiently structured to deal with novel fields that are developing as rapidly
as reproductive genetics. This stems from the fact that the FDA’s mandate
is both too broad and too narrow. The FDA’s authority is too broad because
it encompasses all therapeutics. For example, even the FDA Office of
Cellular, Tissue, and Gene Therapies—the designated proximate overseer of
MRT—is entrusted with a diverse portfolio of cellular, tissue, and gene
therapeutics. 81 On the other hand, FDA’s authority is too narrow for it
extends only to (i) drugs, (ii) biologics and (iii) and devices.82 Thus, the
FDA must proceed on the premise that MRT constitutes a drug or a
biological product.83 In other words, novel scientific advances must be
manipulated and jerry-rigged to fit the FDA’s current and outdated threecategory framework. The necessity of having to classify every potential
genetic engineering technology as a drug, biologic, or device is a regulatory
challenge and creates an environment of uncertainty. The resulting
confusion may have a chilling effect among scientists and investors who
shy away from potential breakthroughs due to the unpredictability of
whether the FDA will exert jurisdiction over new technologies and under
which category it will be classified. By stunting investment and critical
scientific research, the U.S. risks losing its edge and its market share to
areas with more fluid and predictable regulations such as the UK.84

78

Id.
Id.
80
Id.
81
Kelly, supra note 32, at 342.
82
See id. at 342–43.
83
Id.
84
See Christopher J.P. Velis, Ambiguity from FDA Stunts Growth in the US, While
Innovation Flourishes in Europe, REG. AFF. PROF. SOC’Y (Jul. 23, 2013),
http://www.raps.org/Regulatory-Focus/Features/Transfered-Features/2013/07/
23/9202/Ambiguity-from-FDA-Stunts-Growth-in-the-US-While-InnovationFlourishes-in-Europe/.
79
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V. OPTION THREE: A NEW INDEPENDENT REGULATORY AGENCY
Congress could enact legislation authorizing the creation of a new
regulatory agency focused specifically on the oversight of reproductive and
genetic biotechnologies. This would be comparable to agencies that exist in
other countries such as the Assisted Human Reproduction Agency (AHRA)
in Canada and the Human Fertilisation and Embryology Authority (HFEA)
in the United Kingdom.85
The creation of an independent agency addresses many of the
shortcomings of the current patchwork regulation in the U.S. and of ceding
oversight authority to the FDA. Thus, it may be the best option to maximize
the safety and well-being of research participants, promote public debate,
and ensure the continued advancement of scientific progress in the United
States. The recent “exemplary” success of the “regulatory adjudication of
MRT” by the HFEA is illustrative of the capacities of an independent
agency.86 The UK regulatory experience may also provide invaluable
insight into how a similar agency in the United States could be structured.

A. The New Agency and Safety & Well-Being
First, the creation of an independent regulatory agency will better
maximize the safety and well-being of research participants. An agency
tasked with the responsibilities and regulatory authority of an IRB would be
able to adequately perform scientific and ethical reviews of all germline
research protocols and procedures.87 In addition, the “new agency could be
authorized to directly consider policy concerns that extend beyond the
FDA’s purview of safety and efficacy.”88 By appointing individuals with
more specialized expertise, a new agency will be more competent than the
FDA in dealing with the complex array of social, ethical, and legal issues
implicated by germline modifications.89
The success of such an independent regulatory agency has been
demonstrated by the HFEA in the United Kingdom. The HFEA is
responsible “for licensing and monitoring clinics and laboratories involved
in gamete or embryo storage, creation, or use, and the act sets out the
purposes for which licenses will be required . . . .”90 The HFEA establishes
and publishes a code of practice that acts as a source of guidance for
85

See Erin L. Nelson, Comparative Perspectives in the Regulation of Assisted
Reproductive Technologies in the United Kingdom and Canada, 43 ALBERTA L.
REV. 1023, 1023 (2006).
86
Adashi, supra note 1, at 1331.
87
Kelly, supra note 32, at 344-46.
88
Id.
89
See id.
90
Parens & Knowles, supra note 31, at S15.
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patients, clinics, and clinicians as to the proper conduct of actions carried on
under a HFEA license.91 “Through the setting of standards and the provision
of licenses, the HFEA provides both quality control and assurances that
ethical conduct in embryo research is maintained.”92 If the U.S. creates a
similar independent agency with the ability to oversee germline research
and clinical application at a federal level, the government will be able to
better ensure both scientific quality assurance and greater certainty that
ethically unacceptable activities will not be conducted behind the closed
doors of the private sector.

B. The New Agency and Public Debate
The limited interaction between private institutions and the FDA
with the public stands in stark contrast to what can be accomplished by an
independent regulatory agency. For example, the difference between the
relative weight assigned to public consultation on regulatory issues by the
FDA and the HFEA is staggering. In the UK, the “public consultation
process was an extensive outsourced multimethod (e.g., surveys and
workshops) effort on a national scale lasting 6 months,”93 and has been
praised to be “nothing short of exemplary in its focus on safety, ethics, and
public receptivity.”94 The vetting process in the United States, on the other
hand, has been described as “a work in progress.”95
The flexibility provided by the creation of a new independent
regulatory agency can be used to establish a system that can foster the
discussion of safety and well-being concerns with the greater public. This is
particularly important in the United States, where the lack of uniform
oversight for reproductive technologies can be partially attributed to the
deep and divisive debate around the issue of abortion.96 In the backdrop of
the polarizing and volatile dynamics of this debate, many policymakers
have been reluctant to join the conversation, which has greatly hampered
the regulation and advancement of assisted reproductive technologies.97
If reproductive genetic research is to be taken seriously, both sides
must begin to join the conversation and find way to compromise.
Discussions regarding MRT can no longer be isolated to select experts in
the FDA or relegated to individual researchers and their private financial
backers. A new independent agency separate from the political arena with a
91

Id.
Id.
93
Cohen et al., supra note 58, at 180.
94
Adashi, supra note 1, at 1331.
95
Id.
96
See Parens & Knowles, supra note 31, at S11.
97
Id.
92

No. 1]

DUKE LAW & TECHNOLOGY REVIEW

135

diverse board along the lines of the HFEA will help ensure that the concerns
of both sides of the abortion debate are taken seriously.98 Members of the
board may be appointed by a bipartisan committee, with representation
from all of the stakeholders involved.99 Such an independent agency will
allow engagement with the public, increase understanding, and build
consensus among traditionally hostile groups.

C. The New Agency and Scientific Progress
Despite the traditional belief that more regulations result in greater
restrictions on innovation, a new regulatory agency would likely accelerate
future research and development of reproductive genetic technologies.
Several lessons can be drawn from the UK regulatory paradigm regarding
the continued progress of scientific advancement. Clinical trials in the UK
began as early as October 2015, whereas the FDA has essentially put a stop
to all MRT research in the United States.100
1. Specialized and Expert Nature
First, the HFEA is a specialized agency whose sole charge is to
regulate reproductive technologies.101 Thus, the HFEA was more capable
and expert in their treatment of MRT, which was viewed “as a
circumscribed outgrowth of related and highly familiar technologies (e.g., in
vitro fertilization) rather than as a therapeutic.” 102
The creation of a new independent agency in the United States
would allow the appointment of individuals with more specialized expertise
who will be more competent than the FDA in dealing with the complex
array of social, ethical, and legal issues implicated by germline modification
technologies.103 Further, germline modification research would no longer
need to be manipulated and interpreted to fit into the FDA’s existing threecategory framework.
2. Ability to Foster National Pride
Second, MRT research was a tremendous source of pride in the
UK.104 “For better or worse, the parliamentary debate has proceeded with an
air of national pride. Even those opposed to MRT noted their admiration for
the world-class work . . . .”105 One commentator believed “that this national
98
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sense of pride may have swayed some votes in support of MRT.”106 Despite
the fact that researchers in the United States have made equally important
discoveries in this area, American scientists have not enjoyed the same
fanfare.107 A new regulatory agency could potentially accelerate future
research and development of germline modification technologies, if national
attention can be brought to the issue, which has previously remained largely
inaccessible to the general public.108
3. Flexibility to Deal with Novel Innovations
Third, the HFEA was provided with the mechanisms necessary to
deal with new innovations and novel application of existing technologies.
For example:
The authority of the HFEA to grant licenses is limited by the purposes
described in the act. The decision to articulate the purposes of embryo
usage rather than specific techniques has ensured that the act can
incorporate novel techniques that were not envisaged when the act was
drafted. In addition, if new techniques and applications merge that fall
outside the HFEA’s statutory authority, the act allows parliament to
expand the range of purposes that are placed under the HFEA’s
authority, thereby ensuring that new purposes do not call for new
oversight agencies and preserving the integrity of the system.109

Recognizing that it may be nearly impossible to keep pace with
scientific and technological developments, Congress should consider
providing the new independent agency in the United States with similar
mechanisms to accommodate and adapt to contemporary developments in
technology, information and public opinion.
4. Clarity
Finally, a national and specialized agency would provide clear and
unified regulatory guidance. Germline modification research would no
longer need to be manipulated and interpreted to fit into the FDA’s existing
three-category framework. The bureaucratic roadblocks that result from the
current patchwork of oversight between the FDA, NIH, independent
agencies and state legislation could be avoided.
Additional steps may be taken to further ensure clarity. For
example, the HFEA publishes a code of practice to provide information to
“patients, clinics, and clinicians alike” as to the “proper conduct of activities
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carried on in pursuance of a license . . . .” 110 Thus, the HFEA is not seen as
merely a regulatory roadblock to be overcome, but as a source of guidance.
The support in the United Kingdom for the HFEA extends to the
scientific and regulatory communities, which appear to have worked
out a cooperative relationship. When a clinic cannot be licensed due to
insufficient standards or protocols, the HFEA works with that clinic to
ensure that it understands what is required to successfully apply for a
license. Despite the comprehensive and highly centralized regulation,
the United Kingdom remains committed to scientific freedom, and
arguably has one of the most liberal embryo research policies in the
world.”111

A new independent agency in the United States could similarly
provide clarity and promote cooperation through the development of a code
of practice designed to guide and educate patients, researchers, and
clinicians. A more predictable system will encourage investment and ensure
that the U.S. does not fall behind in the advancement of scientific progress.

CONCLUSION
It is clear that the regulatory treatment of germline modification
technologies in the U.S. and the U.K. have diverged significantly.112
Questions about why these differences exist, whether they should they exist
and what it means for some hypothetical future innovation, can no longer be
dismissed as academic exercises. The future has arrived and “MRT
represents but one of a growing complement of novel reproductive
technologies, many of which will require expert regulatory adjudication.”113
With precedent set by the international community and escalating pressure
from within the country,114 Congress must soon decide whether and how to
regulate MRT. Its decision may lay the foundation for how all advances in
this field will be dealt with in the future.
The current patchwork of regulations and the FDA are both illequipped to deal with the complex issues involved. Instead, Congress
should consider enacting legislation to authorize the creation of a new
regulatory agency focused specifically on the oversight of reproductive and
genetic biotechnologies. The process will not be easy but the results may
well be worth the effort. The bedrock formed by clear and unified
regulatory guidance would allow for the maximization of safety and wellbeing for research participants and patients, foster much needed public
110
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conversation, and stimulate scientific progress in a crucial field at the
cutting-edge of science.

